| Zugriffe | |
|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 527 |
| April 2025 | Mai 2025 | Juni 2025 | Juli 2025 | August 2025 | September 2025 | Oktober 2025 | |
|---|---|---|---|---|---|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 4 | 1 | 8 | 13 | 8 | 22 | 16 |
| Zugriffe | |
|---|---|
| diss_f.niehr.pdf | 299 |
